Latest headlines

Novartis AG News

Q: Why is Novartis AG up or down today?

Novartis AG (NVS) moves on news. The headlines above show what is driving NVS today; cross-check the reaction against its Fear and Greed Index and trading volume.

Q: How often is Novartis AG news updated?

The Novartis AG (NVS) news feed refreshes continuously as new stories are published.

Q: How does Novartis AG news relate to its Fear and Greed Index?

News drives sentiment and sentiment drives price. Read Novartis AG news alongside its Fear and Greed Index to separate noise from a real shift in mood.

The latest Novartis AG (NVS) news, aggregated as it breaks. News moves sentiment and sentiment moves price, so read these NVS headlines next to the live Novartis AG Fear and Greed Index.

Latest Novartis AG Headlines53

3 Dividend Stocks to Buy for a Lifetime of Passive Income

fool.com · Jul 29, 2026

Novartis: The Buy Thesis Is Back (Rating Upgrade)

seekingalpha.com · Jul 22, 2026

Novartis AG (NVS) Q2 2026 Earnings Call Transcript

seekingalpha.com · Jul 21, 2026

Novartis CEO on 2Q Profit Beat, Investing in Pipeline

youtube.com · Jul 21, 2026

Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well

zacks.com · Jul 21, 2026

Q2 Earnings Pick Up Steam: GM, MMM, DHI & More

zacks.com · Jul 21, 2026

Novartis Q2 Earnings Call Highlights

marketbeat.com · Jul 21, 2026

Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics

zacks.com · Jul 21, 2026

5 Things to Know Before the Stock Market Opens on Tuesday

investopedia.com · Jul 21, 2026

Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline

benzinga.com · Jul 21, 2026

Novartis CEO Vas Narasimhan says 'no change of plans'

reuters.com · Jul 21, 2026

Novartis Q2 surpasses estimates despite 50% Entresto sales drop

invezz.com · Jul 21, 2026

Novartis Returns to Growth on Sales Momentum From Key Drugs

wsj.com · Jul 21, 2026

Novartis Q2 profit up as generic competition mounts

reuters.com · Jul 21, 2026

Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed

globenewswire.com · Jul 21, 2026

Novartis Earnings Preview: Can New Medicines Offset Generic Pressure and Growing U.S. Pricing Risks?

fxempire.com · Jul 20, 2026

For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?

fool.com · Jul 20, 2026

Novartis faces drug pipeline test with valuation premium in focus

reuters.com · Jul 20, 2026

Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?

zacks.com · Jul 17, 2026

Gear Up for Novartis (NVS) Q2 Earnings: Wall Street Estimates for Key Metrics

zacks.com · Jul 16, 2026

How To Build A $50,000 Dividend Portfolio In Today's Market

seekingalpha.com · Jul 13, 2026

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

fool.com · Jul 9, 2026

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

fool.com · Jul 9, 2026

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger

marketbeat.com · Jul 8, 2026

Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon

seekingalpha.com · Jul 7, 2026

Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition

zacks.com · Jul 6, 2026

Novartis to Buy Myricx Bio for Up to $1.5 Billion

wsj.com · Jul 6, 2026

Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

reuters.com · Jul 6, 2026

NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population

zacks.com · Jul 2, 2026

3 European Stocks to Carry Investors Through the Back Half of 2026

marketbeat.com · Jul 1, 2026

Novartis Eyes $5 Billion Pluvicto Opportunity

gurufocus.com · Jun 25, 2026

Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis

reuters.com · Jun 24, 2026

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies

businesswire.com · Jun 24, 2026

Biotech's Silent Resurgence (5-Year Base Breakout)

zacks.com · Jun 23, 2026

Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study

zacks.com · Jun 15, 2026

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

globenewswire.com · Jun 12, 2026

Novartis says rare muscle disease drug shows promise in early trial

reuters.com · Jun 11, 2026

Novartis Reports Positive Data for Neuromuscular Disorder Drug

zacks.com · Jun 11, 2026

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

zacks.com · Jun 11, 2026

Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study

benzinga.com · Jun 11, 2026

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

etftrends.com · Jun 11, 2026

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

globenewswire.com · Jun 11, 2026

Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines

businesswire.com · Jun 10, 2026

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

globenewswire.com · Jun 8, 2026

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

zacks.com · Jun 5, 2026

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

globenewswire.com · Jun 4, 2026

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

globenewswire.com · Jun 3, 2026

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

fool.com · Jun 2, 2026

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

globenewswire.com · Jun 1, 2026

Experimental Novartis radiopharma drug shows promise in early study

reuters.com · May 31, 2026

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

globenewswire.com · May 31, 2026

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

globenewswire.com · May 26, 2026

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

globenewswire.com · May 21, 2026

Why Is Novartis AG Up or Down Today?

When Novartis AG (NVS) moves sharply, the reason is almost always in the headlines above. Earnings, guidance, analyst upgrades and downgrades, product news and macro data are the usual drivers of a NVS move on the day. The feed shows what broke and when, and the sentiment tag on each story shows whether the coverage skews positive or negative, so you can see at a glance why Novartis AG is up or down today.

How Novartis AG News Affects the Price

News does not move the Novartis AG (NVS) price directly, it moves sentiment, and sentiment moves price. A run of negative headlines pulls the Novartis AG Fear and Greed Index toward fear, while positive coverage pushes it toward greed, often before the price has fully reacted. A surprise story usually shows up first as a spike in Novartis AG trading volume. That is the chain to watch: headline, sentiment, volume, then the NVS price.

Trade the Novartis AG News With Sentiment

Headlines tell you what happened; the Fear and Greed Index tells you how the crowd is reacting. Watch Novartis AG trading volume spike on a big story, check the Novartis AG price history for context, follow the live NVS price, see the Novartis AG price prediction, and read the Novartis AG Fear and Greed Index for mood.

How do you feel about Novartis AG?

Frequently asked questions

Why is Novartis AG up or down today?

Novartis AG (NVS) moves on news, and the headlines above are the fastest way to see what is driving NVS today, from earnings, guidance and analyst moves to the broader market mood. Cross-check the reaction against the live Novartis AG Fear and Greed Index and NVS trading volume.

What is the latest Novartis AG news?

The newest Novartis AG (NVS) headlines are listed above, most recent first, each linking to the original source. We pull the last 60 stories so you can scroll the full recent NVS news cycle in one place.

Where does Novartis AG news come from?

We aggregate Novartis AG (NVS) headlines from financial news wires and refresh them continuously. Each headline links straight to the original source.

How often is Novartis AG news updated?

Continuously. The Novartis AG (NVS) feed refreshes as new stories are published, so the headlines at the top are the freshest available.

How does Novartis AG news relate to its Fear and Greed Index?

News drives sentiment, and sentiment drives price. A run of negative headlines tends to push the Novartis AG Fear and Greed Index toward fear, positive coverage toward greed. Reading them together is how you separate noise from a real shift in mood.

Headlines are aggregated from third-party sources and link to the original publishers. CFGI does not author or endorse them.

About CFGI

The per-asset sentiment record.

CFGI is a market sentiment data company that scores crowd emotion from 0 to 100 across crypto and stock markets. Crypto readings cover the whole market and hundreds of individual assets across 15-minute, 1-hour, 4-hour and daily views. The stock index gives a live daily reading for wider stock market sentiment.

Every CFGI score is built from 10 indicators: price, volatility, volume, impulse, technical analysis, social media, dominance, search interest, whale movements and order book pressure. The same data powers our API, alerts and embeddable widgets.